TLDR Recombinant Human Annexin A5 may help treat localized scleroderma by reducing skin thickening and inflammation.
The study demonstrates that recombinant human Annexin A5 (AnxA5) has significant anti-fibrotic and anti-inflammatory effects in treating localized scleroderma (LoS). AnxA5 inhibits the TGF-β/Smad2 signaling pathway in dermal fibroblasts, reducing collagen synthesis and secretion, and modulates macrophage activity to decrease inflammation. In murine models, both systemic and topical applications of AnxA5 effectively reduced fibrosis and inflammation, with preventative treatment showing superior efficacy. These findings suggest AnxA5 as a promising therapeutic candidate for LoS and potentially other fibrotic skin diseases, with ongoing research needed to optimize delivery methods and dosage.
August 2023 in “Stem Cell Research & Therapy” A substance called Cell-free fat extract can effectively treat common hair loss by increasing hair growth and density.
2 citations
,
January 2023 in “Dermatologic Therapy” CEFFE injections effectively and safely improve postinflammatory hyperpigmentation.
19 citations
,
November 2011 Using systemic drugs as creams for skin conditions shows promise, but more research is needed to confirm their effectiveness and safety.
54 citations
,
January 2023 in “Signal Transduction and Targeted Therapy” New therapies are being developed that target integrin pathways to treat various diseases.
33 citations
,
January 2018 in “Blood” Ruxolitinib helps protect skin stem cells and keeps skin healthy in mice with skin GVHD.
2 citations
,
October 2015 in “Human Gene Therapy” The congress highlighted new gene therapy techniques and cell transplantation methods for treating diseases.
341 citations
,
November 2009 in “The FASEB Journal” Calreticulin has roles in healing, immune response, and disease beyond its known functions in the endoplasmic reticulum.
September 2004 in “Experimental dermatology” Melatonin directly affects mouse hair follicles and may influence hair growth.